Chest
-
COPD Epidemiology & Physiology PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: European respiratory society (ERS) guidelines recommend to stratify patients with acute exacerbations of COPD (AECOPD) according to the presence or not of risk factors(RF) for Pseudomonas aeruginosa (PA). There is controversy regarding the need to empirically cover PA in clinical practice. Therefore a better understanding of the prevalence and RF for PA in hospitalized patients with AECOPD is critical in order to appropriately adhere to clinical practice guidelines. Aim: 1) Determine the prevalence of PA pathogens and PA risk RF in hospitalized patients with AECOPD; and 2) Assess the association of PA isolation and PA RF among hospitalized patients with AECOPD. ⋯ The following authors have nothing to disclose: Pedro Marcos, Pilar Sanjuan, Santiago Rodriguez-Segade, Natalia Uribe-Giraldo, Marina Blanco-Aparicio, Isabel Otero, Jorge Ricoy, Hector Verea, Marcos RestrepoNo Product/Research Disclosure Information.
-
Bronchoscopy and Interventional Procedures PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: To know about the degree of patients' tolerance of the endobronchial ultrasound (EBUS) using different sedation models. ⋯ The following authors have nothing to disclose: José Ferrando, Iker Fernández-Navamuel, Carmen Centeno Clemente, Pere Vila, Javier Flandes, Felipe Andreo, Andrés Briones, Enrique Cases ViedmaNo Product/Research Disclosure Information.
-
Pulmonary Hypertension Posters ISESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: The etiological spectrum of pulmonary arterial hypertension (PAH) in Eastern European countries seems to be different from Western Europe. The reasons for this have not been explained. The aim was to describe the differences in the etiology between prevalent and newly diagnosed PAH cases in Slovakia, a Central-Eastern European country. ⋯ The following authors have nothing to disclose: Milan Luknar, Peter Lesny, Eva GoncalvesovaNo Product/Research Disclosure Information.
-
AsthmaSESSION TYPE: Slide PresentationsPRESENTED ON: Saturday, March 22, 2014 at 12:15 PM - 01:15 PMPURPOSE: Several studies have shown that there is significant clinical improvement, better control of symptoms and reduce of oral corticosteroids and itraconazol, in patients with ABPA treated with omalizumab. The aim of the study was to determine the effect of omalizumab treatment on clinical efficacy in 6 ABPA patients. ⋯ The following authors have nothing to disclose: María del Valle Somiedo Gutiérrez, Carolina Cisneros, Rosa Girón Moreno, Gilda Fernandes Vasconcelos, Gonzalo Segrelles, Silvia SanchezOmalizumab treatment is not already indicated but there are some reports about successful response to Omalizumab in cystic fibrosis or asthma complicated with ABPA.
-
Critical Care Posters ISESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: Apnea testing may demonstrate loss of ventilatory brain stem function; however it can cause hypotension, hypoxia and cardiac arrhythmias. These complications create barriers for the completion of the test, leading to additional confirmatory studies being performed, such as cerebral angiography or nuclear imaging. End-tidal carbon dioxide level (EtCO2) has been frequently documented as a surrogate for partial pressure of carbon dioxide (PaCO2). Additionally, lung sliding is known to detect pleural movement during ventilation. We investigated if absence of lung sliding, in conjunction with comparing pre- and post-apnea test EtCO2, is effective as a strategy to detect lack of ventilation during an apnea test. ⋯ The following authors have nothing to disclose: Adaira Landry, Young Im LeeNo Product/Research Disclosure Information.